When does PharmaTher report earnings and what to expect?

PharmaTher's earnings announcement is scheduled for 23 Jan 2026. Expect updates on Phase II/III ketamine trials, cash runway commentary, and any guidance that could change near‑term funding needs.

What are the main valuation metrics for PHRM.CN stock?

Key metrics: price **C$0.09**, EPS **-0.02**, PE **-4.50**, market cap **C$8,191,716.00**, book value per share **C$0.0086**. These show a small market cap and negative profitability.

How reliable is Meyka AI's forecast for PHRM.CN?

Meyka AI's forecast model projects **C$0.278** in 12 months, implying 208.94% upside versus **C$0.09**. Forecasts are model‑based projections and not guarantees; they should complement independent research.

Is PHRM.CN stock liquid enough for active trading?

Liquidity is limited. Today’s volume of **339,900** exceeded the average **88,785**, but the low absolute price and wide spreads increase execution risk. Use limit orders and monitor bid‑ask spreads on CNQ.

CA Stocks

PHRM.CN PharmaTher (CNQ) C$0.09 on 22 Jan 2026 ahead of earnings: trial catalysts

ByHuzaifa Zahoor January 22, 2026January 22, 2026

PHRM.CN stock is trading at C$0.09 on 22 Jan 2026 as investors position ahead of an earnings announcement on 23 Jan 2026. Volume is active at 339,900 shares versus an average of 88,785, signaling market attention. Key drivers for PharmaTher Holdings Ltd. (PHRM.CN) on the CNQ exchange include Phase II/III ketamine trial updates and cash runway metrics. We summarise where valuation, technicals, and company guidance could move the stock during market hours.